|
|
Article: Researchers from Medical School, Department of Internal Medicine report recent findings in arthritis.(Report)
- Article from:
- Biotech Week
- Article date:
- July 1, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
New research, 'Efficacy of high-throughput leukocytapheresis for rheumatoid arthritis with a reduced response to infliximab,' is the subject of a report. According to recent research from Kanagawa, Japan, "Infliximab (INF), a tumor necrosis factor-alpha (TNF-alpha) inhibitor, is an effective drug for patients with rheumatoid arthritis (RA). However, some patients receive no clinical benefit, or the agents gradually lose their effect."
"Five sessions of high-throughput leukocytapheresis (LCAP) were given at a frequency of once a week using a Cellsorba CS-180S to four patients with a reduced response to INF. The clinical response to LCAP was evaluated using the ...
Related newspaper, magazine, and journal articles:
|
|
Article: Researchers from Medical School, Department of ...
Obesity & Diabetes Week;
January 19, 2009 ;
700+ words
... ... and colleagues, Medical School, Department of Internal Medicine (see also Obesity ... contact N.C. Leite, Medical School, Dept. of Internal Medicine, University Hospital ... Clementino Fraga Filho, Medical School, Rio de Janeiro ...
|
|